STOCK TITAN
  1. Home
  2. News
  3. PRME

Prime Medicine - PRME STOCK NEWS

Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.

Prime Medicine, Inc. (Nasdaq: PRME) is at the forefront of biotechnology with a mission to deliver next-generation genetic therapies aimed at addressing a wide spectrum of diseases. Leveraging its proprietary Prime Editing platform, the company uses precise and efficient gene editing technology to develop potentially curative genetic therapies. Prime Editing allows for targeted modifications at specific genomic sites, which can repair almost all types of genetic mutations with minimal unwanted DNA changes. This versatile technology holds promise for treating genetic disorders affecting various tissues, organs, and cell types.

Prime Medicine is currently advancing a diversified portfolio of eighteen programs, initially focused on genetic diseases with high unmet medical needs. Some of the company's key projects include therapies for Chronic Granulomatous Disease (CGD) and Cystic Fibrosis (CF). In recent news, the U.S. Food and Drug Administration (FDA) has cleared Prime Medicine's Investigational New Drug (IND) application for PM359, intended to treat CGD. This marks a significant milestone as PM359 is the first-ever Prime Editor product candidate to advance to clinical trials.

Financially, the company reported robust results for the year ended December 31, 2023, and remains committed to progressing its clinical programs. Prime Medicine also emphasizes collaborations and partnerships to accelerate its innovative work. A notable recent development includes its amicable settlement with Myeloid Therapeutics, Inc., allowing both companies to pursue their scientific and commercial goals unimpeded.

Prime Medicine's commitment to innovation extends to tackling Cystic Fibrosis through Prime Editing technology. The company plans to correct CFTR mutations using two distinct strategies: hotspot editing and the Prime Assisted Site Specific Integrase Gene Editing (PASSIGE™). With funding from the Cystic Fibrosis Foundation, Prime Medicine aims to develop therapies that could potentially cure the disease.

In summary, Prime Medicine is a pioneering biotechnology firm dedicated to transforming genetic therapy. Its cutting-edge Prime Editing platform and focus on high unmet medical needs make it a significant player in the field of gene editing.

News

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Rhea-AI Summary
Prime Medicine reports new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct mutations of glycogen storage disease 1b (GSD1b) in non-human primates and mouse models. The data show up to 83% of hepatocytes and up to 50% of the whole liver were precisely edited in NHPs, with no safety concerns observed. In humanized GSD1b mouse models, up to 56% of the whole liver was edited. No detectable off-target edits were observed. The findings support the further advancement of Prime Medicine's Prime Editors for GSD1b and other liver-targeted programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
none
-
News

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Rhea-AI Summary
Prime Medicine reports new preclinical data demonstrating the ability of Prime Editors to correct mutations causing RHO adRP. The data show up to 70% precise correction at RHO p.P23H mutation and up to 65% at RHO p.V345L and p.P347L mutations. No detectable AAV genome integration or off-target edits were observed. The results highlight the potential of Prime Editing in treating ophthalmological indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
News

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Rhea-AI Summary
Prime Medicine, Inc. will showcase advances in preclinical data across the Prime Editing pipeline and platform at healthcare industry conferences in October and November 2023. The presentations will cover various diseases and highlight the efficacy and safety of Prime Editing in treating genetic mutations. The company's lipid nanoparticle and all-RNA delivery platforms will also be discussed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
clinical trial
News

Prime Medicine to Present at Upcoming Investor Conferences

Rhea-AI Summary
Prime Medicine, Inc. (Nasdaq: PRME) announces CEO's participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
-
News

Prime Medicine to Present at Upcoming Investor Conferences

Rhea-AI Summary
Prime Medicine, Inc. to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
News

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Rhea-AI Summary
Prime Medicine, a biotechnology company (Nasdaq: PRME), reported Q2 2023 financial results with a cash balance of $221.1 million. They showcased new preclinical data at ASGCT Annual Meeting demonstrating Prime Editing's ability to correct CGD causative mutation and entered a strategic collaboration with Cimeio Therapeutics. The company is on track to initiate IND-enabling studies of PM359 for CGD in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
earnings
News

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

Rhea-AI Summary
Prime Medicine and Cimeio Therapeutics are collaborating to combine their technologies in order to improve the safety and effectiveness of hematopoietic stem cell transplants and in vivo genetic therapies. The collaboration aims to reduce toxicity of conditioning regimens and introduce new therapeutic options. Prime Medicine will develop a Prime Editor for Cimeio's CD117 shielding variant, and if successful, the companies will grant exclusive license options to each other for their technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
-
News

Prime Medicine to Present at Investor Conferences in June

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
conferences
-
News

Prime Medicine to Present at Virtual Investor Conferences in May

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
News

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

Rhea-AI Summary
Prime Medicine, Inc. presented new preclinical data at the ASGCT 26th Annual Meeting. The data demonstrated the potential of Prime Editing to correct the causative mutation of chronic granulomatous disease (CGD) and the ability of the Prime Editing Assisted Site-Specific Integrase Gene Editing (PASSIGE™) platform to generate multiplex-edited CAR-T cells. The CGD program showed highly reproducible Prime Editing with no off-target editing detected. The PASSIGE platform showcased the insertion of a CD19-CAR at the TRAC genetic locus in primary human T cells and efficient knock-out of the B2M gene.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
conferences clinical trial

FAQ

What is the current stock price of Prime Medicine (PRME)?

The current stock price of Prime Medicine (PRME) is $2.52 as of February 28, 2025.

What is the market cap of Prime Medicine (PRME)?

The market cap of Prime Medicine (PRME) is approximately 317.4M.

What is Prime Medicine, Inc.?

Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company focused on delivering next-generation genetic therapies using its proprietary Prime Editing platform.

What is Prime Editing?

Prime Editing is a precise and efficient gene editing technology that allows targeted modifications at specific genomic sites to repair genetic mutations with minimal unwanted DNA changes.

What diseases is Prime Medicine targeting?

Prime Medicine is advancing therapies for a range of genetic diseases, including Chronic Granulomatous Disease (CGD) and Cystic Fibrosis (CF), among others.

What is PM359?

PM359 is Prime Medicine's first product candidate targeting Chronic Granulomatous Disease (CGD). It has received FDA clearance for clinical trials, marking a significant milestone for the company.

What recent developments have occurred at Prime Medicine?

Recent developments include the FDA's clearance of PM359 for CGD treatment, a financial report showcasing robust results for 2023, and an amicable settlement with Myeloid Therapeutics, Inc.

How is Prime Medicine addressing Cystic Fibrosis?

Prime Medicine is using Prime Editing technology to correct CFTR mutations in Cystic Fibrosis patients through hotspot editing and the Prime Assisted Site Specific Integrase Gene Editing (PASSIGE™) strategies.

What are the financial expectations for Prime Medicine?

Prime Medicine reported strong financial results for 2023 and continues to advance its portfolio of clinical programs, expecting further growth as it transitions into a clinical-stage company.

Who are Prime Medicine's key partners?

Prime Medicine collaborates with various organizations, including the Cystic Fibrosis Foundation, to advance its genetic therapy programs. It recently resolved disputes with Myeloid Therapeutics, Inc., to focus on collaborative goals.

What is the significance of the recent FDA clearance for PM359?

The FDA clearance for PM359 allows Prime Medicine to initiate clinical trials, marking the first-ever advancement of a Prime Editor product candidate to the clinic. This is a significant milestone for the company and gene editing field.

Where can I find more information about Prime Medicine?

For more information about Prime Medicine, visit their official website at www.primemedicine.com.
Stock PRME logo
Prime Medicine

Nasdaq:PRME

PRME Rankings

#2198 Ranked by Market Cap
N/A Ranked by Dividends

PRME Stock Data

317.41M
99.81M
23.91%
62.47%
13.12%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE